Effects of Hydralazine and Increased Cardiac Output on Recombinant Tissue Plasminogen Activator-Induced Thrombolysis in Canine Pulmonary Embolism*

This publication has 20 references indexed in Scilit:

• Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
  Circulation, 1989
• RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM
  The Lancet, 1988
• Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.
  Circulation, 1988
• Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator
  Journal of the American College of Cardiology, 1987
• Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics.
  Circulation, 1987
• Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism.
  Circulation, 1986
• The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits
  Thrombosis Research, 1985
• Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits
  Blood, 1985
• Work in progress: detection of deep venous thrombosis with 99mTc-sulfur colloid.
  Radiology, 1983
• Uptake of⁹⁹Tc^mcolloid by intravascular clot
  The British Journal of Radiology, 1976